A Idaho overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
32.7% of Idaho adults have obesity, per the CDC's 2024 BRFSS data 1 — just under the 33.1% national rate the same year, and the 31st-highest among the 50 states plus D.C., tied with Maryland 1. Idaho sits in the middle of the national range, not at either extreme.
It is also growing fast: Idaho's population crossed 2 million for the first time in 2024 (2,001,619 as of July 1, 2024), the nation's 6th-fastest-growing state that year at +1.55% 2.
Yes, with prior authorization — and the claims data shows exactly when that started. Idaho Medicaid fee-for-service paid $0 for Wegovy (semaglutide) in every quarter of 2023 and Q1 2024, then began paying real claims starting Q2 2024 3 — a dated coverage inflection point, not just policy text.
Zepbound (tirzepatide) claims started later, in Q1 2025, but scaled faster: by Q1 2026, the latest data published, Idaho FFS had paid for 997 Zepbound prescriptions (about $1.057M reimbursed) versus 171 Wegovy prescriptions ($223,626 reimbursed) 3 — Zepbound now runs well ahead in volume. Saxenda (liraglutide), also FDA-approved for chronic weight management, shows zero reimbursed Idaho Medicaid claims across all of 2023–2026 3 — effectively unused in practice.
Coverage requires prior authorization through Idaho's Preferred Drug List 4. The exact clinical and BMI criteria gating that PA sit inside a PDL document that could not be machine-verified 5: treat "covered since Q2 2024, PA required" as confirmed, and the specific PA thresholds as unverified. Federal law still excludes weight-loss agents from mandatory Medicaid drug coverage, which is why this is a state-by-state answer at all 6.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
Idaho residents pay the same as anyone else Astra serves — there is no Idaho rate and no Idaho discount. Real local clinic prices, checked against providers who publish them, are on the Boise page.
Idaho regulates telehealth practice through the Idaho Telehealth Access Act, Idaho Code Title 54, Ch. 57 and Idaho Board of Medicine licensure rules 78.
TODO — the exact requirements for telehealth-based prescribing of anti-obesity GLP-1 medications specifically (any mandated initial-visit type, documentation standard, or controlled-substance carve-out) have not been independently confirmed from the statute or board rule text and need a human to verify directly on the linked sources before being stated as fact.
Open verification item: Idaho Medicaid PDL prior-authorization criteria (BMI thresholds, comorbidity requirements, step therapy) for Wegovy/Zepbound — the PDL PDF sits behind a JS-gated Laserfiche portal that rejects automated fetch and must be opened directly in a browser 5.
Astra serves all 50 states, Idaho included — from Boise to the rural counties where the nearest prescriber is a long drive away.
Astra treats patients in Idaho through state-licensed physicians.
See real GLP-1 prices in Boise — local clinic pricing sourced directly from providers who publish it, shown next to the same national Astra price listed here.
Yes. Idaho Medicaid's own fee-for-service claims data shows real payments starting Q2 2024 for Wegovy (semaglutide) and Q1 2025 for Zepbound (tirzepatide). By Q1 2026, the latest quarter published, Idaho FFS had paid for 171 Wegovy prescriptions ($223,626) and 997 Zepbound prescriptions (about $1.057 million) — Zepbound now runs well ahead of Wegovy in volume. Coverage requires prior authorization through Idaho's Preferred Drug List; check your own plan's current PA rules before assuming coverage. (Source: CMS State Drug Utilization Data, Idaho FFS, 2023–2026; Idaho Dept. of Health & Welfare Medicaid Pharmacy Program.)
No. Astra prices nationally, not by state or city: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually). Idaho residents pay the same price as anyone else Astra serves.
32.7% of Idaho adults have obesity, per the CDC's 2024 BRFSS survey — just under the 33.1% national average, and roughly the 31st-highest rate among the 50 states and D.C. (tied with Maryland). Idaho sits in the middle of the national range, not at either extreme.
Idaho has a dedicated telehealth statute (the Idaho Telehealth Access Act, Idaho Code Title 54, Ch. 57) and the Idaho Board of Medicine regulates physician conduct including telehealth visits. The exact rules for prescribing anti-obesity GLP-1s specifically over telehealth haven't been independently confirmed here and are flagged for verification — check the Board's statutes-and-rules page directly. In practice, telehealth is how many Idahoans in this large, fast-growing, largely rural state reach a GLP-1 prescriber without a long drive to a specialist.
See the Boise page for verified local clinic pricing sourced directly from providers who publish their prices in Boise, shown next to the same national Astra price listed here.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.